RXi Pharmaceuticals Celebrates Expansion of its Operations in Massachusetts
News Jul 05, 2014
RXi Pharmaceuticals Corporation has announced the official opening of its new office and laboratory in the Marlborough Technology Center. The Company will host a ribbon-cutting ceremony on Wednesday, July 9, 2014 from 10:00 -12:00 p.m., at 257 Simarano Drive, Marlborough, MA, to mark the opening of their new facility. The ceremony will be held in collaboration with the Massachusetts Life Sciences Center (MLSC) and MassBio.
"The Company's recent move to Marlborough has allowed us to centralize our employee base," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. "In addition, this facility allows for future growth considerations as we advance our pre-clinical and clinical programs."
RXi Pharmaceuticals was founded in 2011. Since that time, the Company has successfully completed and announced positive results from two Phase 1 clinical studies with our lead compound RXI-109. We have formed two therapeutic franchises, within RXi, based on our areas of focus: Dermatology and Ophthalmology. The Company has continued to progress its dermal clinical program and is currently conducting two Phase 2 studies with a third study planned for initiation this year.
Within our Ophthalmology program, we have obtained positive results, with RXI-109, in the eyes of cynomolgus monkeys. In addition, the Company received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a key patent covering our core, self-delivering RNAi technology (sd-rxRNA®) platform, which sets us apart from the competition and provides us with a powerful advantage to deliver our RNAi compounds without delivery vehicles. We believe we are well positioned for continued success.
The Company is supported by a group of dedicated, professional employees, with strategic guidance provided by a seasoned and successful Board of Directors, and by an accomplished Management and Scientific Advisory Board with significant experience in RNAi therapeutics, dermatology drug development and in building and managing emerging life science companies.
"Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences," said Massachusetts Governor Deval Patrick. "We congratulate RXi Pharmaceuticals on their expansion and look forward to their continued contributions to our thriving life sciences community."
"On behalf of the Center, I would like to extend our warmest congratulations to RXi Pharmaceuticals as the company officially opens its new office and laboratory in Marlborough," said Susan Windham Bannister, Ph.D., President and CEO of the Massachusetts Life Sciences Center, the agency charged with implementing Governor Patrick's 10-year, $1 billion Life Sciences Initiative. "We've enjoyed a long-standing relationship with RXi, and we are pleased to celebrate its ongoing success and growth in Massachusetts."
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018